November 5, 2021 -- IsoPlexis will present data from its IsoLight and IsoSpark platforms at the annual meeting of the Society for Immunotherapy of Cancer (SITC) on November 11 virtually and in person at the Walter E. Washington Convention Center in Washington, DC.
The company will reveal data outlining how to leverage certain proteomically active single cells and their genetic drivers identified simultaneously through single-cell transcriptomics and proteomics analyses on IsoPlexis' Duomic platform. The company said the data has implications for CAR T studies and other applications.
The presentation will take place on Thursday, November 11 from 12:15 to 1:15 p.m. EDT in meeting room 204ABC. Conference attendees can visit the IsoPlexis booth (No. 7) to see the platform. In-booth presentations will be given on Friday, November 12 and Saturday, November 13.